Best Prescription GLP-1 Medications of 2026

For most people seeking the biggest, best-evidenced weight loss, the two strongest options are the FDA-approved injectables tirzepatide (Zepbound/Mounjaro) and semaglutide (Wegovy/Ozempic) — and in the only large head-to-head trial, tirzepatide won. Everything else in this category — oral pills, "compounded" copies, and telehealth front-ends — is best understood as a trade-off against those two anchors, so the smartest move is to match an FDA-approved molecule and a verifiable pharmacy to your goals rather than chasing whatever is cheapest or most advertised.

What are prescription GLP-1 options and how do they work?

GLP-1 medications are prescription drugs that mimic glucagon-like peptide-1, a gut hormone the body releases after eating. By activating GLP-1 receptors, they slow stomach emptying, blunt appetite and food cravings through the brain, and improve the pancreas's insulin response. The net effect is that people eat less, feel full sooner, and lose a clinically meaningful amount of weight — while blood sugar improves in people with diabetes.

The category breaks down into a few distinct mechanisms and formats:

• GLP-1 receptor agonists (single-target). Semaglutide is the dominant molecule, sold as Wegovy (FDA-approved for chronic weight management), Ozempic (approved for type 2 diabetes), and Rybelsus (an oral tablet for diabetes). Older agents include liraglutide (Saxenda/Victoza) and the discontinued exenatide.
• Dual GIP/GLP-1 receptor agonists. Tirzepatide activates both GLP-1 and a second gut hormone receptor (GIP), sold as Zepbound (weight management) and Mounjaro (diabetes). The dual mechanism is the leading theory for why it tends to outperform semaglutide.
• Oral GLP-1 pills. A once-daily oral Wegovy (oral semaglutide 25 mg) was FDA-approved in December 2025 for weight management (FDA). In April 2026 the FDA approved Foundayo (orforglipron), the first small-molecule oral GLP-1 that can be taken any time of day without food or water restrictions (FDA; Eli Lilly).
• Compounded GLP-1s. Pharmacy-made copies of semaglutide and tirzepatide that proliferated during the 2022–2025 shortages. Their legal status has narrowed sharply (see below).

How you receive these matters as much as the molecule. The branded drugs are dispensed by ordinary pharmacies with a prescription; many people instead encounter GLP-1s through telehealth platforms (Ro, Hims, Henry Meds, Found, Calibrate, and others) that pair an asynchronous medical visit with either branded drugs or compounded versions.

What does the evidence actually show?

This is where an honest guide diverges from marketing. Evidence quality varies dramatically across the category, so we label each approach.

• Semaglutide for weight loss — strong. In the pivotal STEP 1 randomized trial (68 weeks, 1,961 adults without diabetes), once-weekly semaglutide 2.4 mg produced a mean 14.9% body-weight reduction versus 2.4% on placebo (NEJM 2021; PMID 33567185). Crucially, the SELECT cardiovascular outcomes trial in 17,604 adults with overweight/obesity and established heart disease (but no diabetes) found semaglutide cut major adverse cardiovascular events (heart attack, stroke, CV death) by 20% versus placebo (hazard ratio 0.80; primary event in 6.5% vs 8.0%) (NEJM 2023; PMID 37952131). That hard-outcome benefit, not just weight loss, is why semaglutide earned an FDA indication to reduce cardiovascular risk.
• Tirzepatide for weight loss — strong, and the most effective. In SURMOUNT-1 (72 weeks, 2,539 adults without diabetes), tirzepatide produced mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% on placebo (NEJM 2022; PMID 35658024). In the only large head-to-head trial, SURMOUNT-5 (751 adults, 72 weeks), tirzepatide drove 20.2% weight loss versus 13.7% for semaglutide, and far more people reached ≥25% loss (31.6% vs 16.1%) (NEJM 2025; PMID 40353578). This is the single best piece of evidence for ranking the injectables.
• Oral semaglutide (Wegovy pill) — strong for the molecule, slightly less proven for the pill. In the OASIS 4 trial, once-daily oral semaglutide 25 mg produced a 16.6% weight reduction at 64 weeks versus 2.7% on placebo (FDA). It draws on the same molecule with years of injectable data behind it.
• Orforglipron (Foundayo) — moderate-to-strong, but more modest. In ATTAIN-1 (72 weeks, 3,127 adults without diabetes), orforglipron produced mean reductions of 7.8% (6 mg), 9.3% (12 mg), and 12.4% (36 mg) (NEJM 2025; FDA; Eli Lilly). The broader ATTAIN registration program enrolled more than 4,500 people across two phase 3 trials, so the data are solid — but the magnitude is lower than the injectables, the trade-off for a convenient daily pill with no food/water timing rules.
• Liraglutide (Saxenda) — moderate, but outclassed. Effective versus placebo but with smaller average weight loss than semaglutide or tirzepatide and a daily-injection burden, making it largely a second-line option today.
• Compounded GLP-1s — limited and now legally restricted. There are no large randomized trials of compounded products themselves — their plausibility rests entirely on borrowing the brand-name molecule's data, which only holds if the compound truly matches the studied drug. The FDA declared the tirzepatide shortage resolved in late 2024 (re-confirmed December 2024) and the semaglutide shortage resolved in February 2025; the enforcement-discretion (grace) periods for 503A pharmacies and 503B outsourcing facilities to mass-produce copies all ended by mid-2025 (tirzepatide by Feb–Mar 2025, semaglutide by Apr–May 2025). In April 2026 the FDA moved to permanently restrict mass-marketed compounded GLP-1s and remove them from the 503B bulk-compounding pathway, and has issued warning letters to compounders (FDA). The agency has logged hundreds of adverse-event reports tied to compounded GLP-1s — more than 455 for compounded semaglutide and more than 320 for compounded tirzepatide — many from dosing errors with multi-dose vials, some requiring hospitalization (FDA).

How to choose: what to look for

1. Start from an FDA-approved molecule. The strongest evidence — and the only cardiovascular-outcomes data — sits with branded semaglutide and tirzepatide. If a program offers these, you are buying the exact drug the trials studied. If it offers a compounded "semaglutide," you are buying something whose match to the studied drug you must take on trust.

2. Match the molecule to your goal.

• Maximum weight loss: tirzepatide has the best head-to-head data.
• Diabetes + weight + heart-disease risk: semaglutide carries the cardiovascular indication.
• Needle aversion or travel: an oral option (oral Wegovy, or Foundayo with no timing rules) trades some efficacy for convenience.

3. Verify the pharmacy, not just the website. A legitimate program routes prescriptions to a licensed U.S. pharmacy you can look up. For any compounded product, insist on knowing whether it comes from a 503A (patient-specific) or 503B (outsourcing facility) pharmacy, whether the base form (not an unstudied salt form like semaglutide sodium/acetate) is used, and whether there is third-party potency and sterility testing.

4. Confirm real clinician oversight. GLP-1s require dose titration and monitoring. Look for a licensed prescriber, a clear plan for stepping up the dose, a way to reach a clinician about side effects, and documented review of your history — not a one-click checkout.

5. Price the all-in cost honestly. Compare the total monthly cost including the drug, the visit, shipping, and any required labs — against what branded Zepbound or Wegovy would cost with manufacturer savings programs or self-pay vials. A low headline price that excludes the visit fee, or that depends on an indefinite subscription, is not a real saving.

What to avoid: common marketing traps

• "Same active ingredient as Ozempic/Wegovy" claims for compounds. Same molecule on paper is not the same as the FDA-approved, tested product — and salt forms, dosing accuracy, and sterility are exactly where compounded products have gone wrong.
• Buying from sites with no prescription. The National Association of Boards of Pharmacy (NABP) reports that roughly 95–96% of websites selling prescription drugs do so illegally — and 96% of those on its Not Recommended list do not require a valid prescription (NABP). A site that ships GLP-1s with no prescription is in this overwhelming-majority illegal category. No-prescription, made-abroad "GLP-1" is a counterfeit risk, not a bargain.
• Multi-dose vials with "draw your own dose." Dosing errors from self-measured vials are a leading source of the FDA's compounded-GLP-1 adverse-event reports — overdoses have led to hospitalization.
• "Microdosing" and "GLP-1 boosters." Supplements and peptides marketed as GLP-1 alternatives (berberine, "nature's Ozempic," unapproved peptides) do not replicate prescription GLP-1 efficacy and are not FDA-approved for weight loss.
• Lifetime-discount lock-ins that hide the real renewal price. Introductory pricing that balloons after the first months can make a compounded plan cost more than the branded drug over a year.

Safety, side effects & who should talk to a doctor first

GLP-1s are generally well tolerated but not benign. The most common effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — usually worst during dose escalation and often easing over time; slow titration reduces them. Less common but serious risks include pancreatitis, gallbladder disease, and dehydration-related kidney injury from severe vomiting (FDA labeling). All agents in this class carry a boxed warning about thyroid C-cell tumors based on rodent studies.

These drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2, and should not be used in pregnancy. Talk to a doctor before starting if you have a history of pancreatitis, gallstones, severe gastrointestinal disease (including gastroparesis), type 1 diabetes, an eating disorder, or are on insulin or sulfonylureas (risk of low blood sugar in combination). Anyone undergoing surgery or anesthesia should disclose GLP-1 use because of delayed stomach emptying. None of this is a reason to avoid the class — it is a reason to use it under genuine medical supervision rather than buying it like a supplement.

Who is this category right for, and who should skip it?

GLP-1 medications are appropriate for adults who meet clinical criteria — typically a BMI ≥30, or ≥27 with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea — and who can commit to ongoing use plus diet and activity changes. They are also a strong fit for people with type 2 diabetes (for glucose control) and, for semaglutide specifically, people with established cardiovascular disease.

You should likely skip or defer this category if you want a small amount of cosmetic weight loss without a medical indication, if you cannot reliably afford continuation (weight tends to return after stopping, so this is a long-term commitment, not a quick course), if you are pregnant or planning pregnancy, or if you fall into the contraindicated groups above. People drawn purely by the lowest-priced compounded vial should weigh the legal and quality risks honestly against the modest savings.

How we evaluate

HealthVetted is independent: we charge nothing for placement and sell no products. For this category we weight strength of human clinical evidence for the molecule at the delivered dose most heavily — favoring FDA-approved drugs with randomized, hard-outcome trials over compounded products that merely borrow that data. We then assess legal and regulatory standing (503A vs. 503B status and response to the FDA's shortage resolution), molecule and formulation transparency (base form vs. unstudied salt forms), pharmacy verifiability and licensure, depth of clinician oversight and dosing-safety design, third-party testing, and honest total cost versus branded alternatives. We make no "we tested it in a lab" claims and cite the FDA, NIH, and peer-reviewed trials. Our full scoring rubric is published at [/methodology](/methodology).

Frequently asked questions

Which GLP-1 causes the most weight loss? In the only large head-to-head trial (SURMOUNT-5), tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks (NEJM 2025). Individual results vary with dose, adherence, and lifestyle, but on average tirzepatide leads.

Is compounded semaglutide still legal? Mass production is largely over. The FDA declared the semaglutide shortage resolved in February 2025 (the tirzepatide shortage was resolved earlier, in late 2024), and 503A pharmacies and 503B outsourcing facilities lost their enforcement-discretion grace periods to make copies by mid-2025; a 2026 FDA action would close the bulk-compounding pathway permanently (FDA). A 503A pharmacy can still compound for an individual patient with a valid prescription in limited circumstances, but the days of cheap, widely available compounded GLP-1s are ending.

Do I have to inject, or can I take a pill? You now have real oral choices. Oral Wegovy (oral semaglutide 25 mg) was FDA-approved in late 2025, and Foundayo (orforglipron) was approved in 2026 with no food-or-water timing rules (FDA). Pills are more convenient but, based on trial data, tend to produce somewhat less weight loss than the strongest injectables.

What happens if I stop? Weight regain is common after discontinuation, because GLP-1s work only while you take them — appetite and metabolic effects fade once the drug clears. Treat this as a long-term therapy and budget accordingly, ideally with a maintenance plan discussed with your prescriber.

Are the side effects dangerous? Most are gastrointestinal and manageable with slow dose escalation. Serious risks (pancreatitis, gallbladder disease, kidney injury from dehydration) are uncommon, and the thyroid-tumor boxed warning is based on rodent data; the class is contraindicated in pregnancy and in those with medullary thyroid cancer history (FDA). This is why a real prescriber and proper titration matter more than the lowest price.